↓ Skip to main content

Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy

Overview of attention for article published in Frontiers in oncology, December 2021
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (71st percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

twitter
9 X users

Readers on

mendeley
18 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
Published in
Frontiers in oncology, December 2021
DOI 10.3389/fonc.2021.789078
Pubmed ID
Authors

Hoyoung M. Maeng, Brittni N. Moore, Hadi Bagheri, Seth M. Steinberg, Jon Inglefield, Kim Dunham, Wei-Zen Wei, John C. Morris, Masaki Terabe, Lee C. England, Brenda Roberson, Douglas Rosing, Vandana Sachdev, Svetlana D. Pack, Markku M. Miettinen, Frederic G. Barr, Louis M. Weiner, Sandhya Panch, David F. Stroncek, Lauren V. Wood, Jay A. Berzofsky

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 18 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 22%
Unspecified 2 11%
Lecturer 2 11%
Professor > Associate Professor 1 6%
Student > Postgraduate 1 6%
Other 0 0%
Unknown 8 44%
Readers by discipline Count As %
Unspecified 2 11%
Immunology and Microbiology 2 11%
Medicine and Dentistry 2 11%
Agricultural and Biological Sciences 1 6%
Pharmacology, Toxicology and Pharmaceutical Science 1 6%
Other 2 11%
Unknown 8 44%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 December 2021.
All research outputs
#7,205,479
of 26,329,145 outputs
Outputs from Frontiers in oncology
#2,402
of 22,974 outputs
Outputs of similar age
#149,703
of 528,231 outputs
Outputs of similar age from Frontiers in oncology
#118
of 1,354 outputs
Altmetric has tracked 26,329,145 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 22,974 research outputs from this source. They receive a mean Attention Score of 3.2. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 528,231 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 1,354 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.